



## ASX ANNOUNCEMENT

7 May 2018

### Allotment and issue of shares under institutional placement and opening of SPP offer

As announced on 30 April 2018, Volpara Health Technologies Limited (**Volpara**) successfully completed a A\$15 million institutional placement at A\$0.60 per share (**Placement**). The shares issued under the Placement will rank equally with existing Volpara fully paid ordinary shares on issue. The shares will be issued within Volpara's existing placement capacity under ASX Listing Rules 7.1 and 7.1A. Allotment and issue of the shares will occur today, 7 May 2018.

In connection with the issue of the shares under the Placement, Volpara provides the following disclosures under ASX Listing Rules 3.10.5A and 7.1A.4(b):

- The dilutive effect of the issue of shares under the Placement on existing shareholders is as follows:

	Number of securities issued	% of post Placement issued share capital
Ordinary shares issued under ASX Listing Rule 7.1	10,450,688	6.13%
Ordinary shares issued under ASX Listing Rule 7.1A	14,549,312	8.53%
<b>Total</b>	<b>25,000,000</b>	<b>14.66%</b>

- Volpara issued shares in a placement to institutional, sophisticated and professional investors (rather than as a pro rata issue) as this was considered to be the most efficient and expedient mechanism for raising funds in a timely manner. Volpara is also undertaking a share purchase plan (**SPP**) for existing eligible shareholders (including retail shareholders) capped at A\$3 million;
- The issue of shares under the Placement was not underwritten; and
- Offer costs (including fees) of approximately \$0.8 million will be incurred in connection with the Placement and the SPP.

### Share Purchase Plan

Volpara is also pleased to announce that it has commenced despatch of the attached SPP offer booklet (**Booklet**), together with a personalised application form, to all eligible shareholders. To be eligible to participate in the SPP you must have been a Volpara shareholder with a registered address in Australia and New Zealand as at 7.00pm (Sydney time) on Friday, 27 April 2018 (**Eligible Shareholder**).

The SPP provides Eligible Shareholders with the opportunity to purchase new shares in Volpara at an issue price of \$0.60 per share. This is the same price at which shares were issued under the Placement.

Upon receipt of the Booklet and personalised application form, Eligible Shareholders who wish to participate in the SPP should follow the instructions in the Booklet and application form if they wish to apply for shares. The offer closes at 5.00pm (Sydney time) on Friday, 25 May 2018 (**Closing Date**) and Eligible Shareholders wishing to participate are encouraged to apply for shares as soon as possible and well in advance of the Closing Date.



## **SPP – key dates\***

<b>Record Date</b> (the time that eligibility to participate in the SPP was determined)	7.00 pm Friday, 27 April 2018
<b>Opening Date</b>	Monday, 7 May 2018
<b>Closing Date</b>	5.00 pm on Friday, 25 May 2018
<b>Completion announcement date (and notice of scale backs, if any)</b>	Tuesday, 29 May 2018
<b>Allotment Date for New Shares</b>	Thursday, 31 May 2018
<b>Despatch of holding statements for New Shares</b>	Thursday, 31 May 2018
<b>New Shares commence trading on ASX</b>	Monday, 4 June 2018

\*This timetable (and each reference in the Booklet to a date specified in the timetable) is indicative only and Volpara may, at its discretion, vary any of the above dates by lodging a revised timetable with the Australian Securities Exchange (**ASX**). All times referred to in the Booklet is Sydney, Australia time.

## **Shareholder enquiries**

Shareholders who have questions in relation to the SPP should contact Volpara's share registry, Boardroom Pty Limited, from 8.30 am to 7.30 pm (Sydney time) Monday to Friday on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) during the offer period.

For further information please contact:

**Ralph Highnam**  
Chief Executive Officer  
+64 21 149 0541

**Craig Hadfield**  
Chief Financial Officer & Company Secretary  
+64 21 840 588

## **About Volpara Health Technologies Limited**

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand, and is a MedTech company focused on the early detection of breast cancer by improving quality of screening using artificial intelligence. Its clinical support software provides real-time feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, assists breast clinics to more efficiently manage their business by providing a centralized overview and wide-ranging benchmarking.

Volpara has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20m through an IPO and subsequent share placement and rights issue in 2016, Volpara has customers and / or research projects in 36 countries.

Further information about Volpara can be found at <https://volparasolutions.com>

## **Not for release to US wire services**

*This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 (as amended, the US Securities Act) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.*